Certara (NASDAQ:CERT) Upgraded to Hold at UBS Group

UBS Group upgraded shares of Certara (NASDAQ:CERT) to a hold rating in a report published on Wednesday,Zacks reports.

Several other brokerages have also recently weighed in on CERT. Barclays lifted their price objective on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.45.

Certara Stock Down 0.6%

CERT stock opened at $9.20 on Wednesday. Certara has a fifty-two week low of $4.45 and a fifty-two week high of $13.88. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -20.44 and a beta of 1.40. The business’s fifty day moving average price is $8.19 and its two-hundred day moving average price is $6.72.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same period in the previous year, the firm posted $0.07 EPS. The company’s revenue was down 10.8% compared to the same quarter last year. On average, equities analysts anticipate that Certara will post 0.22 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new stake in Certara during the second quarter worth about $39,000. NorthRock Partners LLC bought a new position in Certara in the 2nd quarter valued at about $68,000. State of Wyoming bought a new position in Certara in the 2nd quarter valued at about $72,000. Perigon Wealth Management LLC acquired a new position in shares of Certara in the 2nd quarter valued at approximately $80,000. Finally, Quantbot Technologies LP acquired a new position in shares of Certara in the 2nd quarter valued at approximately $82,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara (NASDAQ:CERT) provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.

Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions.